Biologic-exposed UC patients fare better with upadacitinib vs tofacitinib, ustekinumab
In the treatment of ulcerative colitis (UC) patients with prior advanced therapy failure, subsequent treatment with upadacitinib is associated with higher remission rates compared with tofacitinib and ustekinumab, according to the retrospective TRIDENT-UC study.
Biologic-exposed UC patients fare better with upadacitinib vs tofacitinib, ustekinumab
20 Aug 2026